Yong Bin Park

Title: Yong Bin Park: Innovator in Pharmaceutical Chemistry

Introduction

Yong Bin Park is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for cancer treatment. His work focuses on innovative solutions that address critical health challenges.

Latest Patents

Yong Bin Park holds a patent for a pyridine derivative that inhibits RAF kinase and vascular endothelial growth factor receptor. This invention includes a method for preparing the compound, a pharmaceutical composition containing it, and its various uses. The pyridine derivative is designed to inhibit Raf kinase (B-Raf, Raf-1, or B-RafV600E) and VEGFR2, which are involved in angiogenesis. This innovation has potential applications in the prevention or treatment of several types of cancer, including melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, and ovarian cancer, particularly those induced by RAS mutation. He has 1 patent to his name.

Career Highlights

Yong Bin Park has worked with prominent institutions, including the Incheon University Industry Academic Cooperation Foundation and Samjin Pharmaceutical Co., Ltd. His career reflects a commitment to advancing pharmaceutical research and development.

Collaborations

He has collaborated with notable colleagues such as Eui Hwan Cho and Hee Jong Shin, contributing to a dynamic research environment that fosters innovation.

Conclusion

Yong Bin Park's contributions to pharmaceutical chemistry, particularly through his innovative patent, highlight his role as a key figure in the fight against cancer. His work continues to inspire advancements in medical treatments and research.